

Press Release

25 May 2010

e-Therapeutics plc

("e-Therapeutics" or "the Company")

Change of Adviser

e-Therapeutics plc (AIM: ETX), the network drug discovery and development company, is pleased to announce the appointment of Panmure Gordon (UK) Limited as its nominated adviser and broker with immediate effect.

- ends -

For more information:

e-Therapeutics plc

Malcolm Young

www.etherapeutics.co.uk

+44 (0) 191 233 1317

malcolm@etherapeutics.co.uk

Panmure Gordon (UK) Limited

Andrew Burnett

www.panmuregordon.com

+44 (0) 20 7459 3600

Aubrey Powell

Media enquiries:

Abchurch Communications

Heather Salmond / Simone Elviss / Hannah Sharman

www.abchurch-group.com

+44 (0) 20 7398 7704

heather.salmond@abchurch-group.com

Notes to Editors

e-Therapeutics plc is a drug discovery company that pioneered network pharmacology. It has developed proprietary computational systems to swiftly and accurately analyse and predict how medicines interact with cells in the body. This optimises the probability of identifying drug candidates with desirable efficacy and

low toxicity. The Company applies its novel, systematic approach to three areas of activity:

- discovery of new drugs;
- discovering novel uses for existing drugs; and
- analysis of the interactions between different drugs.

Amongst e-Therapeutics' pipeline of compounds in development are novel antibiotics that have been shown to kill the "superbug" MRSA, and a novel cancer chemotherapy that has been shown to kill malignant cells at safe doses in a very short time. Other candidate therapies in development are targeted at atherosclerosis, asthma and depression. The Company is currently in negotiation with a number of pharmaceutical companies, and is progressing the preclinical and clinical development of these products.

For further information on e-Therapeutics visit www.etherapeutics.co.uk.